Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Effect on urapidil on benign prostatic hypertrophy: a multicenter, double-blind study

K Kawabe1, S Tsuchida, J Shimazaki

  • 1Department of Urology, Hamamatsu University School of Medicine, Japan.

Urologia Internationalis
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunologic rejection of the central graft after limbal allograft transplantation combined with penetrating keratoplasty.

Cornea·2001
Same author

Multilayered amniotic membrane transplantation for severe ulceration of the cornea and sclera.

American journal of ophthalmology·2001
Same author

Overexpression of mitogen-activated protein kinase superfamily proteins unrelated to Ras and AF-1 of estrogen receptor alpha mutation in advanced stage human breast cancer.

Pathology, research and practice·2001
Same author

Alternatively spliced MDM2 transcripts in human breast cancer in relation to tumor necrosis and lymph node involvement.

Pathology international·2000
Same author

Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone.

The British journal of ophthalmology·2000
Same author

Combined medical and surgical treatment of severe vernal keratoconjunctivitis.

Japanese journal of ophthalmology·2000

Urapidil effectively treats benign prostatic hypertrophy (BPH) symptoms, with a 60 mg daily dose showing the most benefit. This alpha-1 adrenergic antagonist improved urinary frequency and flow rates in BPH patients.

Area of Science:

  • Pharmacology
  • Urology

Background:

  • Benign prostatic hypertrophy (BPH) is a common condition in aging men.
  • Alpha-1 adrenergic antagonists are a primary treatment for BPH symptoms.

Purpose of the Study:

  • To evaluate the efficacy and safety of urapidil in treating BPH.
  • To determine the optimal dosage of urapidil for BPH management.

Main Methods:

  • Prospective, multicentric, double-blind, placebo-controlled trial.
  • 214 BPH patients randomized into four groups receiving different urapidil dosages or placebo.
  • Treatment duration varied, with follow-up assessments of urinary symptoms and flow rates.

Main Results:

  • All urapidil groups showed significant improvement in urinary frequency and flow rates compared to baseline.

Related Experiment Videos

  • The highest dosage group (60 mg daily) demonstrated a significant reduction in residual urine volume.
  • Investigator-assessed overall impression improved significantly in higher dosage groups (30 mg and 60 mg daily).
  • Side effects were mild and more frequent in higher dosage groups, but not severe.

    • Conclusions:

    • Urapidil is effective in improving BPH symptoms, including urinary frequency and flow.
    • A daily dosage of 60 mg urapidil appears to be the most beneficial for BPH treatment.
    • Urapidil demonstrates a favorable safety profile for BPH management.